{"nctId":"NCT01661790","briefTitle":"Intrapleural Bevacizumab and Cisplatin Therapy for Malignant Pleural Effusion Caused by Non-small Cell Lung Cancer","startDateStruct":{"date":"2009-08"},"conditions":["Malignant Pleural Effusion"],"count":72,"armGroups":[{"label":"Bevacizumab & Cisplatin","type":"EXPERIMENTAL","interventionNames":["Drug: Bevacizumab","Drug: Cisplatin"]},{"label":"Cisplatin","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Cisplatin"]}],"interventions":[{"name":"Bevacizumab","otherNames":["Avastin"]},{"name":"Cisplatin","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients with advanced recurrent or progressive NSCLC proven cytohistologically\n* Karnofsky performance status (KPS) ≥60\n* Life expectancy ≥ 2 months\n* No history of severe diseases of major organs including liver, heart, and kidney\n* No previous intrapleural therapy\n* Written informed consent\n\nExclusion Criteria:\n\n* Active thoracic cavity or systemic bleeding\n* Active pleural or systemic infection.\n* Known sensitivity to Bevacizumab or Cisplatin\n* Refusal to participate in the study.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"85 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With \"Complete Response\" and \"Partial Response\"","description":"Response assessed by type-B ultrasonic tests; Complete remission (CR) was considered when the accumulated fluid had disappeared and was stable for at least four weeks; partial remission (PR) was considered when \\>50% of the accumulated fluid had disappeared, symptoms had improved, and the remaining fluid had failed to increase for at least four weeks; The total efficiency ORR was calculated by taking the sum of CR+PR","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"15","spread":null}]}]}]},{"type":"SECONDARY","title":"Median Progression Free Survival (PFS)","description":null,"paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Overall Survival (OS)","description":null,"paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Adverse Reactions","description":null,"paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Qualify of Life (QoL)","description":null,"paramType":null,"dispersionType":null,"classes":[]},{"type":"OTHER_PRE_SPECIFIED","title":"Quantitative RT-PCR(Reverse Transcription-Polymerase Chain Reaction) for VEGF-A(Vascular Endothelial Growth Factor A)","description":null,"paramType":null,"dispersionType":null,"classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":36},"commonTop":["Leucocytopenia"]}}}